Six-month remission rates with biosimilar versions of rituximab were similar to those seen with the original therapy among adults with the two most common types of ANCA-associated vasculitis (AAV), according to a real-world study in Canada. Data also showed no significant differences in serious adverse events or AAV-related…
Discussion
The presence of clumps of inflammatory cells, or granulomas, in the liver is a rare manifestation of ANCA-associated vasculitis (AAV) that varies widely and can be difficult to diagnose, according to the findings of a new study from Tunisia. While liver problems are common in AAV, the researchers noted…
Discussion
Every time a new ANCA vasculitis clinical trial is announced, I do the same little dance. I read the headline, feel a flicker of hope, and then scroll down to the eligibility criteria looking for one acronym: EGPA, which stands for “eosinophilic granulomatosis with polyangiitis.” Most of the time,…
Becoming educated and informed about ANCA vasculitis is a good first step. Here you’ll find general information such as the diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your ANCA vasculitis journey.
There is no cure for ANCA vasculitis yet, but here you can find more information about current approved treatments, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
